Synlogic, Inc. - SYBX STOCK NEWS

Synlogic, Inc. (Nasdaq: SYBX) and MIT Voigt Lab have been awarded $1 million by the Air Force Research Laboratory (AFRL) as part of their Biotechnology Grand Challenge initiative. This collaboration aims to innovate in the biotechnology field for the Department of Defense. The project will focus on developing engineered strains to create a live bacterial therapeutic intended to enhance pilot performance and decision-making during long missions. The recognition highlights Synlogic's expertise in synthetic biology and its commitment to advancing biotherapeutics.

Synlogic, Inc. (SYBX) announced significant clinical milestones for 2021, including proof of concept data expected for two metabolic programs, SYNB1618 and SYNB8802, targeting Phenylketonuria and Enteric Hyperoxaluria, respectively. The company also advanced SYNB1891 for treating solid tumors and lymphomas. Synlogic ended Q3 2020 with $102.0 million in cash, sufficient to fund operations through 2022. Leadership changes include new appointments to strengthen their R&D capabilities and collaborations with Ginkgo Bioworks for synthetic biology advancements.

On December 14, 2020, Synlogic, Inc. (SYBX) announced that its investigational drug SYNB1891 has advanced into the combination therapy phase of a Phase 1 clinical trial. This drug targets solid tumors and lymphoma through an engineered Synthetic Biotic designed to activate the STING pathway, enhancing the immune response. The trial has shown acceptable safety and scalability, with evidence of immune system upregulation and durable stable disease in some patients. The combination phase with PD-L1 checkpoint inhibitor atezolizumab is set to further explore SYNB1891's therapeutic potential.

Synlogic, Inc. (SYBX) announces the appointment of Michael Heffernan to its board of directors on December 9, 2020. Heffernan brings over 25 years of experience in the biopharmaceutical industry, having held leadership roles in several development-stage companies, including Collegium Pharmaceutical and Avenge Bio. CEO Aoife Brennan expressed confidence in Heffernan's ability to contribute to the company's ongoing progress in synthetic biology, particularly as it enters a pivotal year with multiple clinical opportunities. Synlogic focuses on developing synthetic biotic medicines for metabolic and immunology-related conditions.

Synlogic, Inc. (Nasdaq: SYBX) announced that it will present data on SYNB8802, a Synthetic Biotic medicine for treating Enteric Hyperoxaluria, at the 3rd International Conference on Microbiome Engineering from December 7-9, 2020. Key presentations will cover its development and in silico simulations predicting its activity. SYNB8802 is currently undergoing Phase 1 trials, focusing on safety and urinary oxalate reduction, with results expected in 2021. Enteric Hyperoxaluria affects approximately 250,000 patients in the U.S. and currently lacks approved treatments.

On November 18, 2020, Synlogic, a clinical-stage company focused on synthetic biology, announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. CEO Aoife Brennan will partake in a 'Fireside Chat' at 10:00 am on November 23. Registered attendees can access the presentations from November 23 to December 3, with a live webcast available on the company's website. Synlogic aims to develop Synthetic Biotic medicines for conditions like PKU and HOX, leveraging its unique synthetic biology platform.

Synlogic, Inc. (SYBX) reported its Q3 2020 financial results, highlighting progress in its clinical programs. The company has initiated a Phase 2 study of SYNB1618 for Phenylketonuria (PKU) and commenced a Phase 1 trial for SYNB8802 targeting Enteric Hyperoxaluria. As of September 30, 2020, Synlogic held $102 million in cash. The net loss for the quarter was $13.2 million, slightly improved from $13.3 million in Q3 2019. With no revenue reported this quarter, Synlogic expects a cash runway into 2022, supported by a strengthened leadership team with Dr. David Hava as Chief Scientific Officer.

Synlogic, Inc. (Nasdaq: SYBX) has initiated a Phase 1 clinical study for its investigational Synthetic Biotic medicine, SYNB8802, aimed at treating Enteric Hyperoxaluria (HOX). The first healthy volunteer has been treated ahead of schedule. SYNB8802 is designed to lower urinary oxalate levels, which can cause kidney damage. Preclinical data indicated that SYNB8802 could reduce oxalate levels by 20% to 50% at well-tolerated doses. The study includes a healthy volunteer cohort and patients post-Roux-en-Y gastric bypass, with results expected in 2021.

Synlogic, Inc. (Nasdaq: SYBX) announced it will release its third quarter 2020 financial results on November 5, 2020, before market open. A conference call will follow at 8:30 am ET, available to the public via telephone and webcast. The call will cover financial results and a corporate update. Synlogic focuses on synthetic biology to develop therapeutics for metabolic disorders like Phenylketonuria and Enteric Hyperoxaluria, as well as expanding into immunology and oncology.